Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial.

导出 OA

翻译打印收藏纠错

作者： Jeffrey M,Statland ^[1] ; Dan,Moore ^[2] ; Yunxia,Wang ^[1] ; Maureen,Walsh ^[1] ; Tahseen,Mozaffar ^[3] ; Lauren,Elman ^[4] ; Sharon P,Nations ^[5] ; Hiroshi,Mitsumoto ^[6] ; J Americo,Fernandes ^[7] ; David,Saperstein ^[8] ; Ghazala,Hayat ^[9] ; Laura,Herbelin ^[1] ; Chafic,Karam ^[10] ; Jonathan,Katz ^[2] ; Heather M,Wilkins ^[1] ; Abdulbaki,Agbas ^[11] ; Russell H,Swerdlow ^[1] ; Regina M,Santella ^[6] ; Mazen M,Dimachkie ^[1] ; Richard J,Barohn ^[1] ; Rasagiline Investigators of the Muscle Study Group and Western ALS Consortium

作者单位： Department of Neurology, University of Kansas Medical Center, 3901 Rainbow Boulevard, MS 2012, Kansas City, Kansas, 66160, USA. ^[1] The Forbes Norris MDA/ALS Research Center, California Pacific Medical Center, San Francisco, California, USA. ^[2] Department of Neurology, University of California, Irvine, Irvine, California, USA. ^[3] Department of Neurology, University of Pennsylvania, Philadelphia, Pennslyvania, USA. ^[4] Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. ^[5] Department of Neurology, Columbia University, New York, New York, USA. ^[6] Department of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, USA. ^[7] Phoenix Neurological Associates, Phoenix, Arizona, USA. ^[8] Department of Neurology, St. Louis University, St. Louis, Missouri, USA. ^[9] Department of Neurology, Oregon Health and Science University, Portland, Oregon, USA. ^[10] Department of Biosciences, Kansas City University of Medicine and Bioscience, Kansas City, Missouri, USA. ^[11]

关键词 MAO-B inhibitor amyotrophic lateral sclerosis biomarker controlled clinical trial motor neuron disease randomized rasagiline